ATE283050T1 - Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie - Google Patents

Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie

Info

Publication number
ATE283050T1
ATE283050T1 AT98941662T AT98941662T ATE283050T1 AT E283050 T1 ATE283050 T1 AT E283050T1 AT 98941662 T AT98941662 T AT 98941662T AT 98941662 T AT98941662 T AT 98941662T AT E283050 T1 ATE283050 T1 AT E283050T1
Authority
AT
Austria
Prior art keywords
hyperlipidemia
treatment
delayed release
release compositions
component
Prior art date
Application number
AT98941662T
Other languages
English (en)
Inventor
Michael Myers
Pradeepkumar P Sanghvi
Original Assignee
Biovail Internat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11041609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE283050(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Internat Ltd filed Critical Biovail Internat Ltd
Application granted granted Critical
Publication of ATE283050T1 publication Critical patent/ATE283050T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT98941662T 1997-10-07 1998-07-20 Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie ATE283050T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE19970731A IE970731A1 (en) 1997-10-07 1997-10-07 Product and method for the treatment of hyperlipidemia
PCT/IB1998/001489 WO1999017774A1 (en) 1997-10-07 1998-07-20 Product and method for the treatment of hyperlipidemia

Publications (1)

Publication Number Publication Date
ATE283050T1 true ATE283050T1 (de) 2004-12-15

Family

ID=11041609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98941662T ATE283050T1 (de) 1997-10-07 1998-07-20 Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie

Country Status (9)

Country Link
US (1) US6090830A (de)
EP (1) EP0969838B2 (de)
AT (1) ATE283050T1 (de)
AU (1) AU8995598A (de)
CA (1) CA2273298C (de)
DE (1) DE69827777T9 (de)
ES (1) ES2235357T5 (de)
IE (1) IE970731A1 (de)
WO (1) WO1999017774A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7503493B2 (en) * 1999-10-25 2009-03-17 Silverbrook Research Pty Ltd Method and system for digitizing freehand graphics with user-selected properties
CA2389616A1 (en) * 1999-11-03 2001-05-10 Howard J. Smith & Associates Pty Ltd. Liver selective therapy
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
KR20040091141A (ko) * 2002-03-18 2004-10-27 파마시아 코포레이션 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물
EP1511468A1 (de) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticuläre sterolformulierungen und sterolkombinationen
EP2283864A1 (de) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Flüssige Zusammensetzung enthaltend stabilisierte Wirkstoff-Nanopartikeln
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513145A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
CA2547239A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2549225A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
JP2007513139A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
JP2007513143A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法
PL364348A1 (en) * 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
BRPI0518398A2 (pt) * 2004-12-06 2008-11-18 Reliant Pharmaceuticals Inc Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
WO2007074406A2 (en) * 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
BRPI0708191A2 (pt) * 2006-02-24 2012-05-29 Teva Pharma " composições farmacêuticas de fluvastatina sódica "
DK2026651T3 (da) * 2006-03-08 2013-07-08 Cortria Corp Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
WO2008127893A1 (en) * 2007-04-04 2008-10-23 Hight H Thomas Niacin-based pharmaceutical compositions
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
US20110123609A1 (en) * 2008-07-19 2011-05-26 Sunil Shantwan Borude Multiple unit dosage form of niacin
CN101836987B (zh) * 2009-03-19 2013-03-27 西安万隆制药股份有限公司 一种复方烟酸缓释片
US20190111064A1 (en) * 2017-10-18 2019-04-18 Interstice Therapeutics, LLC Statin + vitamin d combination drug and method of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1255805A (en) * 1967-12-16 1971-12-01 Albert Ag Chem Werke Improvements in delayed release pharmaceutical preparations and stabilisation of vitamins
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5458823A (en) * 1994-10-28 1995-10-17 Fuisz Technologies Ltd. Method and apparatus for spinning feedstock material
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
DE69841395D1 (de) † 1997-07-31 2010-01-28 Abbott Respiratory Llc Zusammensetzung enthaltend einen HMG-CoA-Reduktasehemmer und eine Nikotinsäureverbindung zur Behandlung von Hyperlipidämie

Also Published As

Publication number Publication date
EP0969838A1 (de) 2000-01-12
EP0969838B2 (de) 2010-01-13
DE69827777T2 (de) 2005-12-22
EP0969838B1 (de) 2004-11-24
US6090830A (en) 2000-07-18
CA2273298C (en) 2008-04-08
WO1999017774A1 (en) 1999-04-15
DE69827777T9 (de) 2010-11-11
DE69827777D1 (de) 2004-12-30
ES2235357T5 (es) 2010-03-30
IE970731A1 (en) 2000-10-04
ES2235357T3 (es) 2005-07-01
CA2273298A1 (en) 1999-04-15
DE69827777T3 (de) 2010-07-29
AU8995598A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
DE69827777D1 (de) Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie
SE9704870D0 (sv) New pharmaceutical formulation I
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
AU3006992A (en) Stabilized Pharmeceutical Compositions of HMG-CoA Reductase Inhibitors
DE69907977D1 (de) Pyrrolobenzodiazepine
EP0529854A3 (en) Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as hmg-coa reductase inhibitors
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
TW200517145A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
FI943319A7 (fi) Imidatsolijohdannaiset ja niiden käyttö sytoksiini-inhibiittoreina
MX9308199A (es) Inhibidores de enzima.
PL345030A1 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
MXPA03008045A (es) Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv.
NO942994L (no) Aminoacetylmercaptoacetylamidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
PL331339A1 (en) Antihrombotic and antiarteriosclerotic pharmaceutical composition containing derivative of thiene pyridine as well as an inhibitor of hmg-coa reductase
DE69720778D1 (de) ARZNEIMITTEL ZUR VERZÖGERTEN FREISETZUNG DES HMG-CoA REDUKTASE INHIBITORS FLUVASTATIN
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
HUP0103382A3 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
CU20000140A7 (es) Combinaciones de estatina-carboxialquileter
NO996519D0 (no) Doseringsformer av sertralin med forsinket frigjoering
NO20003758L (no) Trekonserveringsmidler
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
ATE451103T1 (de) Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält
AR021249A1 (es) COMPOSICIoN DE CONFITURA BLANDA NO PEGAJOSA.
BG100248A (bg) Инхибитори на скваленсинтетаза
DE10085183T1 (de) Zubereitung eines HMG-COA Reduktase-Inhibitors mit verlängerter Freisetzungsdauer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties